Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Ines Yasback

Dermatology Atlanta, GA Physician Assistant

NPI 1912487190 CMS profile 11200324

5555 Peachtree Dunwoody Rd Ne Suite 190, Atlanta, GA 30342

Open in the dashboard

General payments

$3,122

176 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ines Yasback of Atlanta, GA is reported in the CMS Open Payments database as having received $3,122 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,050 57
2024 General $1,380 71
2023 General $691 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ines Yasback
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Ines Yasback were reported at $1,050. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Ines Yasback Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $691 $607 $159–$1,674 $160
2024 $1,380 $751 $204–$1,903 $164
2025 $1,050 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,081 67 payments
  2. Novartis Pharmaceuticals Corporation $661 47 payments
  3. Janssen Biotech, Inc. $240 7 payments
  4. Sun Pharmaceutical Industries Inc. $215 7 payments
  5. Regeneron Healthcare Solutions, Inc. $158 6 payments
  6. UCB, Inc. $141 6 payments
  7. Mayne Pharma Inc. $102 7 payments
  8. E.R. Squibb & Sons, L.L.C. $94 5 payments
  9. Incyte Corporation $92 5 payments
  10. Arcutis Biotherapeutics, Inc. $71 4 payments
  11. Other $266 15 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,032 175 payments
  2. Education $90 1 payment
Products named General payments · program years 2023–2025
  1. COSENTYX $646 46 payments
  2. RINVOQ $585 42 payments
  3. SKYRIZI Immunology $245 11 payments
  4. TREMFYA $192 4 payments
  5. SKYRIZI Immunology $177 11 payments
  6. Bimzelx $141 6 payments
  7. DUPIXENT $123 5 payments
  8. SOTYKTU $94 5 payments
  9. SIMPONI ARIA $92 6 payments
  10. STELARA $92 6 payments
  11. Other $753 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

23

Median for Dermatology: 534

Drug cost

$490

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 12 $305
Triamcinolone Acetonide Generic 11 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $257
$257 — —
RINVOQ
  • AbbVie, Inc. $200
$200 — —
TREMFYA
  • Janssen Biotech, Inc. $159
$159 — —
SKYRIZI
  • AbbVie, Inc. $135
$135 — —
Bimzelx
  • UCB, Inc. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record